+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe

Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe

European Journal of Neurology 17(1): 90-96

Cerebrospinal fluid (CSF) biomarkers have been reported to be useful in dementia diagnosis. Not much is known about their use in clinical practice in Europe. We analyzed data from a survey on the use of CSF biomarkers in the diagnosis of dementia across Europe using a questionnaire which was filled out by representatives of the 25 member countries of the European Federation of Neurological Societies (EFNS). Cerebrospinal fluid beta-amyloid, total tau, and phosphorylated tau proteins are frequently evaluated in the majority of the countries (in 18 out of 23 countries). No major technical or ethical issues were found that would hamper the procedure's ability to become routine in early and differential diagnostics of Alzheimer's disease. Cut-off values for beta-amyloid (median 500, range 300-849 pg/ml), total tau (367; 195-450 pg/ml) and phosphorylated tau (60; 40-85 pg/ml) varied considerably amongst countries and even within every country. Cerebrospinal fluid analysis of beta-amyloid, tau, and phosphorylated tau is frequently used in Europe. However, the use of various cut off values seriously hampers comparability and yields a potential threat to an interpretation and balanced use in clinical practice. We recommend that each laboratory establishes normative data and that multi-centered studies should be organized to explore the reasons for any differences.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 056795460

Download citation: RISBibTeXText

PMID: 19659752

DOI: 10.1111/j.1468-1331.2009.02753.x

Related references

Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. Journal of Alzheimer's Disease 60(1): 201-210, 2017

The value of cerebrospinal fluid biomarkers for the differential diagnosis of dementia. Neurodegenerative Disease Management 2(2): 211-219, 2012

Comparative analysis of cerebrospinal fluid biomarkers in the differential diagnosis of neurodegenerative dementia. Alzheimer's and Dementia 12(5): 577-589, 2016

Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia. Journal of Alzheimer's Disease 61(1): 135-143, 2018

Use of cerebrospinal fluid (CSF) biomarkers for Alzheimer's type dementia: diagnosis in mild cognitive impairment. Nederlands Tijdschrift Voor Geneeskunde 157(11): A5596, 2013

Re-evaluation of soluble APP-α and APP-β in cerebrospinal fluid as potential biomarkers for early diagnosis of dementia disorders. Biomarker Research 5: 28, 2017

Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Archives of Neurology 69(11): 1445-1452, 2012

Added Diagnostic Value of Cerebrospinal Fluid Biomarkers for Differential Dementia Diagnosis in an Autopsy-Confirmed Cohort. Journal of Alzheimer's Disease 63(1): 373-381, 2018

Alzheimer's disease dementia as the diagnosis best supported by the cerebrospinal fluid biomarkers: difference in cut-off levels from thai experience. International Journal of Alzheimer's Disease 2012: 212063, 2012

A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia. Dementia and Geriatric Cognitive Disorders 24(6): 434-440, 2007

Impact of Imaging and Cerebrospinal Fluid Biomarkers on Behavioral Variant Frontotemporal Dementia Diagnosis within a Late-Onset Frontal Lobe Syndrome Cohort. Dementia and Geriatric Cognitive Disorders 41(1-2): 16-26, 2016

Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biological Psychiatry 64(10): 850-855, 2008

The Latent Dementia Phenotype δ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment. Journal of Alzheimer's Disease 49(2): 547-560, 2016

Cerebrospinal fluid biomarkers for dementia with lewy bodies. International Journal of Alzheimer's Disease 2010: 536538, 2010

Pre-Analytical Stability Of Novel Cerebrospinal Fluid Biomarkers For Dementia. Alzheimer's & Dementia 14(7): P755-P756, 2018